$1.74 EPS Expected for West Pharmaceutical Services, Inc. (NYSE:WST) This Quarter

Wall Street analysts expect that West Pharmaceutical Services, Inc. (NYSE:WST) will report earnings of $1.74 per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for West Pharmaceutical Services’ earnings, with estimates ranging from $1.68 to $1.85. West Pharmaceutical Services posted earnings of $1.25 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 39.2%. The business is expected to report its next quarterly earnings report before the market opens on Thursday, July 29th.

On average, analysts expect that West Pharmaceutical Services will report full year earnings of $7.16 per share for the current fiscal year, with EPS estimates ranging from $7.07 to $7.40. For the next financial year, analysts forecast that the business will report earnings of $7.75 per share, with EPS estimates ranging from $7.35 to $8.00. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 29th. The medical instruments supplier reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.63. West Pharmaceutical Services had a return on equity of 25.08% and a net margin of 18.19%. The business had revenue of $670.70 million during the quarter, compared to analyst estimates of $614.77 million.

Separately, Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $355.00 price objective on the stock in a report on Wednesday, April 21st.

In other news, insider Silji Abraham sold 2,171 shares of the business’s stock in a transaction that occurred on Monday, May 10th. The stock was sold at an average price of $335.00, for a total value of $727,285.00. Following the sale, the insider now directly owns 6,077 shares of the company’s stock, valued at approximately $2,035,795. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.66% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of WST. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in West Pharmaceutical Services by 0.3% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,268 shares of the medical instruments supplier’s stock worth $2,612,000 after acquiring an additional 31 shares during the last quarter. CSat Investment Advisory L.P. raised its holdings in West Pharmaceutical Services by 28.9% in the 1st quarter. CSat Investment Advisory L.P. now owns 147 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 33 shares during the last quarter. Globeflex Capital L P raised its holdings in West Pharmaceutical Services by 6.3% in the 1st quarter. Globeflex Capital L P now owns 622 shares of the medical instruments supplier’s stock worth $175,000 after acquiring an additional 37 shares during the last quarter. Signaturefd LLC raised its holdings in West Pharmaceutical Services by 15.3% in the 1st quarter. Signaturefd LLC now owns 340 shares of the medical instruments supplier’s stock worth $96,000 after acquiring an additional 45 shares during the last quarter. Finally, Stanley Laman Group Ltd. raised its holdings in West Pharmaceutical Services by 2.6% in the 1st quarter. Stanley Laman Group Ltd. now owns 1,948 shares of the medical instruments supplier’s stock worth $549,000 after acquiring an additional 50 shares during the last quarter. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

NYSE:WST traded up $6.02 during trading hours on Thursday, hitting $373.97. 8,588 shares of the company’s stock traded hands, compared to its average volume of 340,820. The company has a market cap of $27.61 billion, a price-to-earnings ratio of 64.37, a P/E/G ratio of 2.02 and a beta of 0.99. West Pharmaceutical Services has a 52 week low of $252.80 and a 52 week high of $377.19. The company has a fifty day moving average of $351.83. The company has a current ratio of 2.75, a quick ratio of 2.11 and a debt-to-equity ratio of 0.14.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 4th. Stockholders of record on Wednesday, July 21st will be given a $0.17 dividend. The ex-dividend date is Tuesday, July 20th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.18%. West Pharmaceutical Services’s dividend payout ratio is currently 14.29%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.